Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Simply Wall Street determines ONCY fair value at $157 p/s

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Feb 19, 2023 1:03pm

854 Views

Post# 35294351

Simply Wall Street determines ONCY fair value at $157 p/s

on a NPV of $ 8 billion US for ONCY in the mBC indication by itself. Their analysis did not take into consideration either the pancreatic or the colorectal cancer indications. Nor did they take into consideration pelareorep's application in combination with CAR-T, bispecifics or small molecules such as PARP and CDK4/6 inhibitors in multiple other cancer indications.

https://simplywall.st/stocks/ca/pharmaceuticals-biotech/tsx-onc/oncolytics-biotech-shares

<< Previous

Bullboard Posts

Next >>

Thesis Gold makes high-grade discovery at Ring Zone